



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VANDETANIB

Generic	Brand	HICL	GCN	Exception/Other
VANDETANIB	CAPRELSA	37531		

This drug requires a written request for prior authorization.

**GUIDELINES FOR USE**

1. Is the patient currently stable on the requested medication?

If yes, **approve for 12 months by GPID as follows:**

- **If the request is for 300mg tablets: #1 tablet per day.**
- **If the request is for 100mg tablets: for up to #2 tablets per day.**

**APPROVAL TEXT:** Please note that this drug has an important FDA safety warning. For more information, please ask your doctor or pharmacist.

If no, continue to #2.

2. Does the patient have diagnosis of symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease?

If yes, **approve for 12 months by GPID as follows:**

- **If the request is for 300mg tablets: #1 tablet per day.**
- **If the request is for 100mg tablets: for up to #2 tablets per day.**

**APPROVAL TEXT:** Please note that this drug has an important FDA safety warning. For more information, please ask your doctor or pharmacist.

If no, do not approve.

**DENIAL TEXT:** Approval requires a diagnosis of symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease.

---

**RATIONALE**

Ensure appropriate utilization of vandetanib based on FDA approved indication and NCCN guidelines. Vandetanib is recommended as an option for the treatment of recurrent or persistent medullary thyroid carcinoma.

**FDA APPROVED INDICATIONS**

Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

VANDETANIB

REFERENCES

- AstraZeneca Pharmaceuticals LP. Vandetanib package insert. Wilmington, DE. April 2011.
- National Comprehensive Cancer Network, Inc. The NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma. (Version 2.2011).
- Thomson Healthcare. Monograph Name. DRUGDEX® System [database online]. Greenwood Village, CO. Available at: <https://www.thomsonhc.com/hcs/librarian/PFDefaultActionId/pf.LoginAction>. [Accessed: June 22, 2011].

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/14

Created: 05/11

Client Approval: 11/13

P&T Approval: 11/13